Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics refutes short seller claims, confirms growing demand and proper inventory for ASCENIV therapy.
ADMA
$8.86
+$0.18 +2.07%

ADMA Biologics refutes short seller claims, confirms growing demand and proper inventory for ASCENIV therapy.

Market News
27 Mar 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

ADMA Biologics responded to a short seller report alleging misleading business practices, clarifying that demand for its immune globulin product ASCENIV has steadily increased and inventory levels at distributors align with industry standards. The company emphasized ASCENIV's role as a late-line therapy for immune-compromised patients and denied accusations of channel stuffing or undisclosed related party transactions. ADMA also highlighted its clean audits and commitment to providing specialty biologics for immunodeficient patients. Investors are encouraged to review official SEC filings for accurate information.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App